ASH 2023 – the search for a better Ayvakit
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
ASH 2023 – J&J makes menin a three-horse race
But JNJ-75276617 still has much to prove.
A triplet of Keytruda failures
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
SABCS 2023 – SERDs square off in combinations
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
